Jeff Knight was named Chief Development and Operating Officer of Alx Oncology Holdings Inc, effective April 13, 2026. As of November 6, 2026, Alx Oncology Holdings Inc has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 13, 2026 to June 30, 2026, naming 1 appointment and 1 departure (Form 8-K, April 13, 2026).
Who owns Alx Oncology Holdings Inc?
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Alx Oncology Holdings Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Alx Oncology Holdings Inc reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-13 to 2026-06-30. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Alx Oncology Holdings Inc files it.
Also on the record for Alx Oncology Holdings Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 16, 2026 | Stake report, Schedule 13D/A, by venBio Global Strategic Fund, L.P. | 9.99% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Chen Yu | 4.2% of the class | 5%+ stakes | Source |
| July 27, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.4% of the class | 5%+ stakes | Source |
| May 27, 2026 | Stake report, Schedule 13D/A, by LSV Associates, LLC | 2.2% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by HBM Healthcare Investments (Cayman) Ltd. | 6.5% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Redmile Group, LLC | 6.8% of the class | 5%+ stakes | Source |
| April 28, 2026 | Stake report, Schedule 13G/A, by Millennium Management LLC | 1.5% of the class | 5%+ stakes | Source |
| February 9, 2026 | Stake report, Schedule 13G, by RA Capital Management, L.P. | 9.9% of the class | 5%+ stakes | Source |
| February 6, 2026 | Stake report, Schedule 13G, by Chen Yu | 9.9% of the class | 5%+ stakes | Source |
| February 4, 2026 | Stake report, Schedule 13D/A, by venBio Global Strategic Fund, L.P. | 10% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by TANG CAPITAL MANAGEMENT, LLC | — | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by TANG CAPITAL MANAGEMENT, LLC | — | 5%+ stakes | Source |
Selling to them or working with them? See who runs Alx Oncology Holdings Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Alx Oncology Holdings Inc and the records around it.
Alx Oncology Holdings Inc elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- HBM Healthcare Investments (Cayman) Ltd. also filed stake reports on 7 other companies: Chemomab Therapeutics Ltd. (Sep 2026), IO Biotech, Inc. (Apr 2026), Upstream Bio, Inc. (Nov 2025)
- Redmile Group, LLC also filed stake reports on 18 other companies: FATE THERAPEUTICS INC (Nov 2026), Electra Therapeutics, Inc. (Sep 2026), Neurogene Inc. (Aug 2026)
- TCG Crossover GP II, LLC also filed stake reports on 21 other companies: First Tracks Biotherapeutics, Inc. (Aug 2026), Fulcrum Therapeutics, Inc. (Aug 2026), LB Pharmaceuticals Inc. (Aug 2026)
Watch Alx Oncology Holdings Inc
Get an email when Alx Oncology Holdings Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Alx Oncology Holdings Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Alx Oncology Holdings Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Alx Oncology Holdings Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 15 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-30 | Out | 8-K, 2026-06-30 | |||
| 2026-04-13 | In | Chief Development and Operating Officer | 2026-04-13 | 8-K, 2026-04-13 |
Who leads Alx Oncology Holdings Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Development and Operating Officer: Jeff Knight, appointed, effective 2026-04-13 (filed 2026-04-13).
New leaders reset buying decisions — get the Full Report on Alx Oncology Holdings Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Development and Operating Officer at Alx Oncology Holdings Inc, with the record behind each one.
Find candidates like Chief Development and Operating Officer at Alx Oncology Holdings IncEvery change, in the filing's words
Departing: Corey Goodman
Dr. Goodman resigned for personal reasons and not as a result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.
- On June 29, 2026, Corey Goodman, Ph.D. informed ALX Oncology Holdings Inc. (the "Company") of his resignation as Chairman of the Company's board of directors (the "Board") and as a member of the Board, and from all committees thereof, to be effective as of the close of business on June 29, 2026.
Appointed: Jeff Knight, Chief Development and Operating Officer, effective 2026-04-13
Effective April 13, 2026, the Board of Directors (the "Board") of ALX Oncology Holdings Inc. (the "Company") appointed Jeff Knight as Chief Development and Operating Officer.
- Jeff Knight, age 55, served as the Chief Development and Operating Officer at Crinetics Pharmaceuticals, Inc., a global biopharmaceutical company, from September 2021 to April 2026.
- From October 2018 to August 2021, Mr. Knight served as Senior Vice President, Portfolio Management and Corporate Operations at Poseida Therapeutics, Inc., where he was responsible for portfolio management and strategy, alliance management, quality and compliance, and corporate operations.
- From March 2017 until October 2018, he was Vice President, Development Operations and Project and Portfolio Management at Halozyme Therapeutics, Inc. From July 2015 until March 2017, he served as Executive Director, Global Development Operations at Amgen Inc. and from January 2012 until July 2015, Mr. Knight served in various program and portfolio management and development operations roles at Onyx Pharmaceuticals.
- Prior to that, he held several leadership roles of increasing responsibility in clinical operations, regulatory affairs, and project management at Genentech, PRA International, and Hoechst Marion Roussel (now Sanofi).
- Mr. Knight earned a Master's of Public Health in biostatistics and epidemiology from the University of Oklahoma Health Sciences Center and a B.A. in psychology from the University of Oklahoma.
- He also earned a B.S. in nursing from the University of Kansas.
Tools for this story
Each opens in a new tab, filled in for Alx Oncology Holdings Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.